PPD Development, LP /ID# 232134 — Wilmington, North Carolina

PPD Development, LP /ID# 232134 is a clinical research site located in Wilmington, North Carolina, United States 28401-3331.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

PPD Development, LP /ID# 232134 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment.

Sponsors: AbbVie.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for PPD Development, LP /ID# 232134?

PPD Development, LP /ID# 232134 has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has PPD Development, LP /ID# 232134 conducted?

PPD Development, LP /ID# 232134 has 1 clinical trials on record, with 1 currently active. Their work covers Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment.

Is PPD Development, LP /ID# 232134 accredited by Crixeo Health?

PPD Development, LP /ID# 232134 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about PPD Development, LP /ID# 232134?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.